Amarin Corporation plc (AMRN: Quote), a biopharmaceutical company, said Tuesday that additional data from its pivotal MARINE Phase 3 clinical trial are now available electronically through the Journal of Clinical Lipidology.
The publication, titled "AMR101, a Pure EPA Omega-3 Fatty Acid: Effects on Lipoprotein Particle Concentration and Size in Patients with Very High Triglyceride Levels, or the MARINE Study," reports the effects of Vascepa capsules on lipoprotein particle concentrations and sizes in patients with baseline triglyceride levels.
The MARINE trial was a Phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study. The study enrolled 229 patients and investigated Vascepa as a treatment for severe hypertriglyceridemia. The MARINE trial achieved its primary efficacy endpoints as defined in the clinical trial protocol and demonstrated a favorable safety profile.
The AMR101 publication reported that Vascepa reduced median concentrations of large very-low-density lipoprotein, total LDL, small LDL and total high-density lipoprotein particles and reduced VLDL particle size in a patient population with TG >=500 mg/dL.
However, vascepa did not significantly change the overall sizes of LDL or HDL particles.
| || |
| To receive FREE breaking news email alerts for Amarin Corp Plc and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com